The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Q1 2025 Management View CEO Bernard Zovighian outlined that total company sales grew 8% to $1.41 billion in Q1 2025, driven ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement and surgery in patients at low surgical risk. Both groups had improvements in ...

“These patients already had their TAVR,” he said. “So, [is] this related somewhat to the device that may have been used? The operators? The patients themselves? How do you explain that higher stroke ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or ...

Mark Wilterding; Mark Wilterding Senior Vice President, Investor Relations and Treasurer; Edwards Lifesciences Corp. Bernard Zovighian; President, Chief Executive Of ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...